Mechanism of action
Dopamine itself is unable to cross the blood-brain barrier (BBB). Therefore, clinical practice uses its precursor — levodopa (Levodopa), which is the levorotatory isomer of DOPA (L-DOPA).
Levodopa is a weak acid (pKa 2.3) that crosses the blood-brain barrier via active transport using the aromatic amino acid transport system (mimicking the natural substrate). Once in intact CNS neurons, levodopa undergoes decarboxylation by the enzyme DOPA decarboxylase. As a result, it is converted into dopamine, which is released from nerve terminals and stimulates $D_2$ receptors on cholinergic neurons of the neostriatum.
Role of carbidopa: With levodopa monotherapy, more than 90% of the dose is metabolized by DOPA decarboxylase in the intestinal wall and liver. The dopamine formed in the periphery does not enter the brain, which is why the bioavailability of levodopa for the CNS is only 1–3%. Carbidopa is a peripheral DOPA decarboxylase inhibitor. It prevents the premature breakdown of levodopa, increases its concentration in the CNS, and dramatically reduces the frequency of peripheral side effects.
Pharmacological effects and clinical use
Stimulation of $D_2$ receptors leads to a decrease in the pathological hyperactivity of cholinergic neurons. Clinically, this manifests as a powerful antiparkinsonian effect: bradykinesia, muscle rigidity, and tremor are relieved. The drug is considered the most effective treatment for Parkinson's disease.
Dosing regimen: The drug is prescribed orally. The initial dose is 1/2 tablet 1–2 times daily. The maximum recommended daily dose is limited to 0.2 g of carbidopa and 2.0 g of levodopa.
Clinically important: Levodopa is absorbed in the intestine via the aromatic amino acid transport system. Protein-rich foods compete for this transporter and reliably reduce the drug's absorption.
Side effects and complications
Adverse reactions are divided into central (associated with excess dopamine in the brain) and peripheral.
- CNS: Psychosis (due to stimulation of the mesolimbic system), hallucinations, anxiety, depression, insomnia, or conversely, somnolence. For the pharmacological correction of psychosis, the atypical antipsychotic clozapine (Clozapinum) is used. It predominantly blocks $D_4$ receptors while minimally affecting $D_2$, and therefore does not reduce the antiparkinsonian efficacy of levodopa.
- Cardiovascular system: Tachycardia and arrhythmias. These occur due to the stimulation of myocardial $\beta$-adrenoceptors by dopamine formed in the periphery.
- Gastrointestinal tract: Vomiting (resulting from stimulation of the chemoreceptor trigger zone of the vomiting center).
Complications of long-term therapy:
- Dyskinesias: Involuntary choreiform (rapid, irregular) movements of the muscles of the face, neck, and limbs.
- On-off syndrome: Sharp fluctuations in the patient's condition from normal motor activity to a sudden return of symptoms. An attempt to increase the dose often leads to overdose. Extended-release formulations are used for correction.
Contraindications
The drug is strictly contraindicated in the following conditions:
- Narrow-angle glaucoma;
- Diabetes mellitus;
- Severe cardiac arrhythmias;
- History of psychosis;
- Severe hepatic and renal impairment;
- Pregnancy and lactation;
- Pediatric and adolescent age (under 25 years).
Principles of combination therapy
To potentiate the effect of levodopa and preserve endogenous dopamine, a comprehensive approach is used. In addition to DOPA decarboxylase inhibitors (carbidopa), the regimen may include:
- COMT inhibitors (catechol-O-methyltransferase inhibitors) — block an additional pathway of levodopa metabolism.
- MAO-B inhibitors (e.g., selegiline).
- Dopamine-releasing agents (amantadine).
- Dopamine receptor agonists.
Briefly: answers to topical questions
What peripheral side effects does levodopa cause?
- Cardiovascular disorders — changes in heart rhythm manifesting as tachycardia and various types of cardiac arrhythmias.
- Gastrointestinal disorders — dyspeptic symptoms, in particular vomiting, resulting from the stimulation of the chemoreceptor trigger zone of the vomiting center.
Levodopa is a "Trojan horse" that carries dopamine across the blood-brain barrier, while carbidopa is its "shield" protecting it from peripheral enzymes.
Class and exam questions
Why can't dopamine simply be prescribed for parkinsonism?
Dopamine itself is unable to cross the blood-brain barrier, so it will not enter the CNS and will have no effect.
Why is carbidopa needed in the drug formulation?
It inhibits peripheral DOPA decarboxylase. This prevents levodopa from converting into dopamine before reaching the brain, increasing its bioavailability from 1–3% to therapeutically significant levels.
How to manage psychosis caused by levodopa without worsening parkinsonism?
The drug of choice is clozapine. This atypical antipsychotic blocks $D_4$ receptors while having virtually no effect on striatal $D_2$ receptors.
Why is it not recommended to wash down levodopa with a protein shake?
Amino acids from food compete with levodopa for the active transport system of aromatic amino acids in the intestine, which dramatically reduces drug absorption.
What else to study on this topic
- Pathophysiology of Parkinson's disease: the role of the nigrostriatal pathway
- On-off syndrome and pharmacokinetic ways to overcome it
- Comparative characteristics of MAO-A and MAO-B inhibitors
- The role of COMT in catecholamine metabolism
- Specificity of blood-brain barrier transport systems for drugs
Master the entire topic in the «Pharmacology» course
This is a summary. The course covers everything tested in classes and exams.
- Complete study guide on "Levodopa + Carbidopa" and another 5,304 pages of the subject
- Assignments and quizzes after every topic — just like in a colloquium
- AI tutor answers questions on the topic anytime
- 116 video lessons on the subject
Other topics in the «Drugs and Prescriptions» section
Free video lessons: pharmacologyShort lessons with study notes — no registration required.
Prepared by WhiteCoat Pro faculty in accordance with the medical school curriculum. For educational purposes only.